MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

ClinicalTrials.gov ID: NCT03611556

Public ClinicalTrials.gov record NCT03611556. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.

Study identification

NCT ID: NCT03611556
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 213 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 101 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 21, 2018 (Actual)
Primary completion: Jul 22, 2022 (Actual)
Completion: Jul 22, 2022 (Actual)
Last update posted: Oct 3, 2023

2018 – 2022

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 17

Facility	City	State	ZIP	Site status
Research Site	La Jolla	California	92093	—
Research Site	Aurora	Colorado	80045	—
Research Site	Fort Myers	Florida	33901	—
Research Site	Atlanta	Georgia	30322	—
Research Site	Boston	Massachusetts	02114	—
Research Site	Boston	Massachusetts	02215	—
Research Site	Ann Arbor	Michigan	48109	—
Research Site	Buffalo	New York	14263	—
Research Site	Durham	North Carolina	27710	—
Research Site	Cincinnati	Ohio	45219	—
Research Site	Columbus	Ohio	43210	—
Research Site	Philadelphia	Pennsylvania	19111	—
Research Site	Nashville	Tennessee	37203	—
Research Site	Dallas	Texas	75235	—
Research Site	Houston	Texas	77030	—
Research Site	Charlottesville	Virginia	22908	—
Research Site	Seattle	Washington	98109	—
Research Site	Madison	Wisconsin	53705	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03611556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 3, 2023 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03611556 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →